Literature DB >> 21900100

FOLFIRINOX: a small step or a great leap forward?

Andrew H Ko1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21900100     DOI： 10.1200/JCO.2011.37.3464

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  6 in total

Review 1.  The role of the FOLFIRINOX regimen for advanced pancreatic cancer.

Authors:  Thierry Conroy; Céline Gavoille; Emmanuelle Samalin; Marc Ychou; Michel Ducreux
Journal:  Curr Oncol Rep       Date:  2013-04       Impact factor: 5.075

2.  Cost-effectiveness of folfirinox for first-line treatment of metastatic pancreatic cancer.

Authors:  C L Attard; S Brown; K Alloul; M J Moore
Journal:  Curr Oncol       Date:  2014-02       Impact factor: 3.677

3.  Global, multicenter, randomized, phase II trial of gemcitabine and gemcitabine plus AGS-1C4D4 in patients with previously untreated, metastatic pancreatic cancer.

Authors:  B M Wolpin; E M O'Reilly; Y J Ko; L S Blaszkowsky; M Rarick; C M Rocha-Lima; P Ritch; E Chan; J Spratlin; T Macarulla; E McWhirter; D Pezet; M Lichinitser; L Roman; A Hartford; K Morrison; L Jackson; M Vincent; L Reyno; M Hidalgo
Journal:  Ann Oncol       Date:  2013-02-28       Impact factor: 32.976

4.  RABL6A Promotes Oxaliplatin Resistance in Tumor Cells and Is a New Marker of Survival for Resected Pancreatic Ductal Adenocarcinoma Patients.

Authors:  Viviane P Muniz; Ryan W Askeland; Xuefeng Zhang; Sara M Reed; Van S Tompkins; Jussara Hagen; Bradley D McDowell; Anna Button; Brian J Smith; Jamie A Weydert; James J Mezhir; Dawn E Quelle
Journal:  Genes Cancer       Date:  2013-07

5.  Palliative chemotherapy for pancreatic adenocarcinoma: a retrospective cohort analysis of efficacy and toxicity of the FOLFIRINOX regimen focusing on the older patient.

Authors:  Anne Katrin Berger; Georg Martin Haag; Martin Ehmann; Anne Byl; Dirk Jäger; Christoph Springfeld
Journal:  BMC Gastroenterol       Date:  2017-12-06       Impact factor: 3.067

6.  Superior therapeutic efficacy of nab-paclitaxel over cremophor-based paclitaxel in locally advanced and metastatic models of human pancreatic cancer.

Authors:  N V Rajeshkumar; Shinichi Yabuuchi; Shweta G Pai; Zeen Tong; Shihe Hou; Scott Bateman; Daniel W Pierce; Carla Heise; Daniel D Von Hoff; Anirban Maitra; Manuel Hidalgo
Journal:  Br J Cancer       Date:  2016-07-21       Impact factor: 7.640
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.